Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA).

Central nervous system (CNS); RNA splicing modifier; SMN protein; SMN1 gene; SMN2 gene; neuromuscular disorders; risdiplam; spinal muscular atrophy (SMA); Pharmacology (medical); Pharmacology; General Medicine

Abstract :

[en] INTRODUCTION: Spinal muscular atrophy (SMA) is a rare autosomal recessive neuromuscular disease which is characterised by muscle atrophy and early death in most patients. Risdiplam is the third overall and first oral drug approved for SMA with disease-modifying potential. Risdiplam acts as a survival motor neuron 2 (SMN2) pre-mRNA splicing modifier with satisfactory safety and efficacy profile. This review aims to critically appraise the place of risdiplam in the map of SMA therapeutics. AREAS COVERED: This review gives an overview of the current market for SMA and presents the mechanism of action and the pharmacological properties of risdiplam. It also outlines the development of risdiplam from early preclinical stages through to the most recently published results from phase 2/3 clinical trials. Risdiplam has proved its efficacy in pivotal trials for SMA Types 1, 2, and 3 with a satisfactory safety profile. EXPERT OPINION: In the absence of comparative data with the other two approved drugs, the role of risdiplam in the treatment algorithm of affected individuals is examined in three different patient populations based on the age and diagnosis method (newborn screening or clinical, symptom-driven diagnosis). Long-term data and real-world data will play a fundamental role in its future.

Disciplines :

Neurology
Pediatrics

Author, co-author :

Markati, Theodora ; MDUK Oxford Neuromuscular Centre, Department of Paediatrics, University of Oxford, Oxford, UK ; Department of Paediatric Neurology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

Fisher, Gemma ; MDUK Oxford Neuromuscular Centre, Department of Paediatrics, University of Oxford, Oxford, UK ; Department of Paediatric Neurology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

Ramdas, Sithara ; MDUK Oxford Neuromuscular Centre, Department of Paediatrics, University of Oxford, Oxford, UK ; Department of Paediatric Neurology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

Servais, Laurent ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pédiatrie ; MDUK Oxford Neuromuscular Centre, Department of Paediatrics, University of Oxford, Oxford, UK ; Department of Paediatric Neurology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

Language :

English

Title :

Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA).

Publication date :

11 April 2022

Journal title :

Expert Opinion on Investigational Drugs

ISSN :

1354-3784

eISSN :

1744-7658

Publisher :

Informa UK Limited, England

Pages :

1-11

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2022.2056836

Funders :

Onassis Foundation [GR]

Commentary :

Oneline ahead of print.

Available on ORBi :

since 26 April 2022

Statistics

Number of views

32 (3 by ULiège)

Number of downloads

1 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Lefebvre S, Bürglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995; 80: 155–165.
Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy–a literature review. Orphanet J Rare Dis. 2017; 12: 124.
Crawford TO, Pardo CA. The neurobiology of childhood spinal muscular atrophy. Neurobiol Dis. 1996; 3: 97–110.
Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol. 2012; 11: 443–452.
Tisdale S, Pellizzoni L. Disease mechanisms and therapeutic approaches in spinal muscular atrophy. J Neurosci. 2015; 35: 8691–8700.
Shababi M, Lorson CL, Rudnik-Schöneborn SS. Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease? J Anat. 2014; 224: 15–28.
Yeo CJJ, Darras BT. Overturning the paradigm of spinal muscular atrophy as just a motor neuron disease. Pediatr Neurol. 2020; 109: 12–19.
Singh RN, Ottesen EW, Singh NN. The first orally deliverable small molecule for the treatment of spinal muscular atrophy. J Exp Neurosci. 2020; 15: 263310552097398.
Dhillon S. Risdiplam: first approval. Drugs. 2020; 80: 1853–1858.
Ramdas S, Servais L. New treatments in spinal muscular atrophy: an overview of currently available data. Expert Opin Pharmacother. 2020; 21: 307–315.
Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus Sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017; 377: 1723–1732.
Mercuri E, Muntoni F, Baranello G, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021; 20: 832–841.
Kakazu J, Walker NL, Babin KC, et al. Risdiplam for the use of spinal muscular atrophy. Orthop Rev (Pavia). 2021; 13: 25579.
Servais L, Baranello G, Scoto M, et al. Therapeutic interventions for spinal muscular atrophy: preclinical and early clinical development opportunities. Expert Opin Investig Drugs. 2021; 30: 519–527.
Pinard E, Green L, Reutlinger M, et al. Discovery of a novel class of survival motor neuron 2 splicing modifiers for the treatment of spinal muscular atrophy. J Med Chem. 2017; 60: 4444–4457.
Naryshkin NA, Weetall M, Dakka A, et al. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science. 2014; 345: 688–693.
Ratni H, Karp GM, Weetall M, et al. Specific correction of alternative survival motor neuron 2 splicing by small molecules: discovery of a potential novel medicine to treat spinal muscular atrophy. J Med Chem. 2016; 59: 6086–6100.
Ratni H, Ebeling M, Baird J, et al. Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). J Med Chem. 2018; 61: 6501–6517.
Campagne S, Boigner S, Rüdisser S, et al. Structural basis of a small molecule targeting RNA for a specific splicing correction. Nat Chem Biol. 2019; 15: 1191–1198.
Sivaramakrishnan M, McCarthy KD, Campagne S, et al. Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers. Nat Commun. 2017; 8: 1476.
Poirier A, Weetall M, Heinig K, et al. Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs. Pharmacol Res Perspect. 2018; 6: e00447.
EVRYSDI: prescribing information [Internet] Last accessed March 2022. Available from: https://www.gene.com/download/pdf/evrysdi_prescribing.pdf
Sturm S, Günther A, Jaber B, et al. A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier. Br J Clin Pharmacol. 2019; 85: 181–193.
Baranello G, Darras BT, Day JW, et al. Risdiplam in Type 1 spinal muscular atrophy. N Engl J Med. 2021; 384: 915–923.
Finkel RS, McDermott MP, Kaufmann P, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014; 83: 810–817.
Kolb SJ, Coffey CS, Yankey JW, et al. Natural history of infantile‐onset spinal muscular atrophy. Ann Neurol. 2017; 82: 883–891.
Darras BT, Masson R, Mazurkiewicz-Bełdzińska M, et al. Risdiplam-treated infants with Type 1 spinal muscular atrophy versus historical controls. N Engl J Med. 2021; 385: 427–435.
De Sanctis R, Coratti G, Pasternak A, et al. Developmental milestones in type I spinal muscular atrophy. Neuromuscul Disord. 2016; 26: 754–759.
Kolb SJ, Coffey CS, Yankey JW, et al. Baseline results of the Neuro NEXT spinal muscular atrophy infant biomarker study. Ann Clin Transl Neurol. 2016; 3: 132–145.
Servais L, Baranello G, Masson R, et al. FIREFISH Part 2: efficacy and safety of risdiplam (RG7916) in infants with Type 1 spinal muscular atrophy (SMA) (1302). Neurology. 2020; 94: 1302.
Mercuri E, Baranello G, Boespflug-Tanguy O, et al. Risdiplam in Types 2 and 3 Spinal Muscular Atrophy: a randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment at the pivotal dose (submitted).
Muntoni F, Bertini E, Comi G, et al. Long-term follow-up of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) treated with olesoxime in the OLEOS trial. Neuromuscul Disord. 2020; 30: 959–969.
Annoussamy M, Seferian AM, Daron A, et al. Natural history of Type 2 and 3 spinal muscular atrophy: 2‐year NatHis‐SMA study. Ann Clin Transl Neurol. 2021; 8: 359–373.
Mercuri E, Deconinck N, Mazzone ES, et al. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2022; 21: 42–52.
Chiriboga C, Bruno C, Duong T, et al. EP.279 JEWELFISH: safety, pharmacodynamic and exploratory efficacy data in non-naïve patients with spinal muscular atrophy (SMA) receiving risdiplam. Neuromuscul Disord. 2021; 31: S134–S135.
Finkel RS, Farrar MA, Vlodavets D, et al. RAINBOWFISH: preliminary efficacy and safety data in risdiplam-treated infants with presymptomatic SMA. Muscular Dystrophy Association Clinical and Scientific Conference; 2022 Mar 13-16; Nashville, USA
Baranello G, Servais L, Bertini E, et al. Pooled safety data from the risdiplam clinical trial development program. British Paediatric Neurology Association; 2022 Jan; Virtual Congress.
Sergott RC, Amorelli GM, Baranello G, et al. Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy. Ann Clin Transl Neurol. 2021; 8: 54–65.
Dangouloff T, Botty C, Beaudart C, et al. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Orphanet J Rare Dis. 2021; 16: 47.
Boemer F, Caberg J-H, Beckers P, et al. Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium. Sci Rep. 2021; 11 (1): 19922.
Glascock J, Sampson J, Connolly AM, et al. Revised recommendations for the treatment of infants diagnosed with spinal muscular atrophy via newborn screening who have 4 copies of SMN2. J Neuromuscul Dis. 2020; 7: 97–100.
Dangouloff T, Servais L. Clinical evidence supporting early treatment o patients with spinal muscular atrophy: current perspectives. Tcrm. 2019; 15: 1153–1161.
Pera MC, Coratti G, Berti B, et al. Diagnostic journey in spinal muscular atrophy: is it still an odyssey? PLoS One. 2020; 15: e0230677.
Dangouloff T, Vrščaj E, Servais L, et al. Newborn screening programs for spinal muscular atrophy worldwide: where we stand and where to go. Neuromuscul Disord. 2021; 31: 574–582.
Dangouloff T, Burghes A, Tizzano EF, et al. 244th ENMC international workshop: newborn screening in spinal muscular atrophy May 10-12, 2019, Hoofdorp, The Netherlands. Neuromuscul Disord. 2020; 30: 93–103.
Deng S, Lee BH, Ciafaloni E. Parent perceptions in choosing treatment for infants with spinal muscular atrophy diagnosed through newborn screening. J Child Neurol. 2021 37; 43–49.
Hagenacker T, Wurster CD, Günther R, et al. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol. 2020; 19: 317–325.
Rudnik-Schöneborn S, Vogelgesang S, Armbrust S, et al. Digital necroses and vascular thrombosis in severe spinal muscular atrophy. Muscle Nerve. 2010; 42: 144–147.
Deguise M-O, Chehade L, Kothary R. Metabolic dysfunction in spinal muscular atrophy. Int J Mol Sci. 2021; 22: 5913.
Carey KA, Farrar MA, Kasparian NA, et al. F amily, healthcare professional, and societal preferences for the treatment of infantile spinal muscular atrophy: a discrete choice experiment. Dev Med Child Neurol. 2021. (Online ahead of printing). DOI: 10.1111/dmcn.15135.
Chabanon A, Seferian AM, Daron A, et al. Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: baseline data NatHis-SMA study. PLoS One. 2018; 13: e0201004.
Lilien C, Reyngoudt H, Seferian AM, et al. Upper limb disease evolution in exon 53 skipping eligible patients with Duchenne muscular dystrophy. Ann Clin Transl Neurol. 2021; 8: 1938–1950.
Fouarge E, Monseur A, Boulanger B, et al. Hierarchical Bayesian modelling of disease progression to inform clinical trial design in centronuclear myopathy. Orphanet J Rare Dis. 2021; 16: 3.
Bertini E, Dessaud E, Mercuri E, et al. Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017; 16: 513–522.
Trundell D, Skalicky A, Staunton H, et al. Development of the SMA Independence scale-upper limb module (SMAIS-ULM): a novel scale for individuals with Type 2 and non-ambulant Type 3 SMA. J Neurol Sci. 2022; 432: 120059.